Renal Function, Metformin, and Iodinated Contrast in an Emergency
A 67-year-old man with type 2 diabetes mellitus (metformin 1 g twice daily), hypertension, and known chronic kidney disease presents to the emergency department with 12 hours of severe right flank pain, fever 38.6°C, and rigors. Bedside ultrasound shows right hydronephrosis with echogenic debris. The surgical team requests an urgent contrast-enhanced CT urogram to plan drainage. His most recent eGFR (3 months ago) was 38 mL/min/1.73 m²; today's creatinine has not yet returned. He is oliguric, has a systolic blood pressure of 96 mmHg, and has received 1 L of crystalloid. The pharmacy asks whether metformin should be stopped, and the surgeon asks whether the contrast study can proceed now.
1. Should the contrast-enhanced CT proceed now? Justify your answer with attention to the clinical urgency and renal risk.
Read the worked answer
- The presentation suggests obstructive pyelonephritis with possible abscess or emphysematous change - a time-critical diagnosis. The benefit of an immediate contrast-enhanced study to define obstruction, collection, and drainage route generally outweighs the risk of contrast-associated acute kidney injury (CA-AKI).
- Current consensus: contrast should not be withheld solely because of reduced eGFR, especially in urgent settings. The historical threshold of eGFR 30 is not an absolute contraindication.
- Risk-reduction measures: ensure adequate volume status (he is hypotensive and oliguric - resuscitation should continue, but do not delay drainage for it), use a low-osmolar nonionic agent at the lowest diagnostic dose, avoid repeat contrast within 48–72 hours if possible, and stop nephrotoxic co-medications where feasible.
- The most important intervention for this patient's kidneys is relief of obstruction, not avoidance of contrast. Delay risks sepsis progression.
- If the patient were unstable or the question could be answered with non-contrast CT plus ultrasound, those alternatives could be considered - but here the surgical plan depends on vascular and collecting-system detail.
2. What is the evidence-based advice about metformin around this contrast study?
Read the worked answer
- Metformin itself is not nephrotoxic, and the concern is metformin-associated lactic acidosis if AKI develops and metformin accumulates.
- Modern guidance (ACR and others) is that in patients with eGFR ≥30 and no acute kidney injury, metformin need not be stopped routinely around iodinated contrast; renal function should be checked if there is concern.
- This patient has eGFR ~38, is oliguric, and is at high risk of AKI - so the situation is different. Reasonable practice: withhold metformin at the time of the acute illness/contrast study, monitor renal function, and restart after 48 hours only if renal function has not deteriorated and the patient is eating and drinking normally.
- The key point for the exam: the decision is driven by the risk of AKI and drug accumulation, not by a fixed rule that all patients stop metformin for 48 hours after contrast.
3. How would you document and follow up renal safety after the study?
Read the worked answer
- Record baseline creatinine/eGFR (today's value is pending - obtain it), volume status, contrast agent, dose, and indication.
- Post-hydration if appropriate and continued monitoring of urine output and creatinine at 48–72 hours.
- Avoid additional nephrotoxins (NSAIDs, aminoglycosides) and avoid repeat iodinated contrast within the at-risk window unless essential.
- Communicate the plan to the surgical and primary teams, and document the shared decision that urgency justified contrast despite CKD.